Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Ipamorelin vs Sermorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Ipamorelin and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Ipamorelin

Anecdotal + Phase 2

Sermorelin

Discontinued (FDA approval 1990; US withdrawal 2008)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: headache; injection site reactions. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Ipamorelin Sermorelin
Class Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist GHRH analog
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release
Route SC injection SC injection
Half-life ~2 hrs ~10-20 min
Dosage (research) 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) 200-500 mcg SC at bedtime daily
Evidence tier Anecdotal + Phase 2 Discontinued (FDA approval 1990; US withdrawal 2008)
Research depth 64 indexed (PubMed 42 · CT 3 · EPMC 19) 149 indexed (PubMed 122 · CT 17 · EPMC 10)
Availability Compounding Restricted Compounding Restricted
Reported risks Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical Injection site reactions; headache; flushing

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Ipamorelin or Sermorelin?

Ipamorelin and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.

What is the difference between Ipamorelin and Sermorelin?

Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; Sermorelin is classed as GHRH analog. Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: Ipamorelin, ~2 hrs; Sermorelin, ~10-20 min. Routes in published studies: Ipamorelin, SC injection; Sermorelin, SC injection.

Which has stronger evidence, Ipamorelin or Sermorelin?

Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies.

Which is more accessible, Ipamorelin or Sermorelin?

Neither Ipamorelin nor Sermorelin is an FDA-approved drug. Catalog status: Ipamorelin, Compounding Restricted; Sermorelin, Compounding Restricted. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are Ipamorelin and Sermorelin ever combined?

Ipamorelin and Sermorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…